Watch the key takeaways in prostate cancer from ASCO20 Virtual by Professor Eric ...

Do patients with non-metastatic castration-resistant prostate cancer exist or do they all have metastases if submitted to a PET scan? See Eric J. Small’s MEDtalk and hear his thoughts on the ...

Professor Martin Reck explains the background for CheckMate 9LA-study and the effect of the combination of nivolumab and ipilimumab + 2 cycles of chemotherapy as first-line treatment of stage IV/recurrent non-small cell lung ...

In this MEDtalk, Eric J. Small, MD and principal investigator of the SPARTAN study describes what characterizes the group of patients with non-metastatic castration-resistant prostate ...

In this MEDtalk, Eric J. Small, MD and principal investigator of the SPARTAN study, explains the clinical benefits from early treatment of patients with non-metastatic castration-resistant prostate ...

Non-small-cell lung cancer (NSCLC) stage III patients are inoperable and are offered chemotherapy or radiation therapy if the patient’s performance status allows it. However, no reduction in relapse is achieved, and the five-year survival rate of this treatment is low. The anti-PD-L1 checkpoint inhibitor pembrolizumab has shown long-term clinical efficacy as first-line treatment in metastatic ...

The 3 KEYNOTE-189 study has compared pembrolizumab, plus pemetrexed and platinum versus placebo plus pemetrexed-platinum as first-line therapy in patients with metastatic, non-squamous, non-small cell lung cancer without sensitizing EGFR of ALK mutation, regardless of PD-L1 aspiration. The final analysis of the study was presented at this year’s ASCO20 congress by Delvys Rodriguez-Abreu, medical oncologist ...

Osimertinib is a tyrosine kinase inhibitor that inhibits both activating EGFR mutations and the EGFR T790M resistance mutation. The question is whether osimertinib can be used at an earlier stage of the disease in a patient group, where the majority is getting progression and frequent central nervous system metastases. The ADAURA study has evaluated osimertinib ...

Non-metastatic castration-resistant prostate cancer (nmCRPC) is characterized by an increase in prostate-specific antigen (PSA), serum testosterone at castrate level (<0.5 ng / l or 1.7 nmol / l) and no detected distant metastases in conventional imaging tests, including bone scan. NmCRPC is considered high risk in cases where the PSA doubling time is 10 months ...

A three-year update from the CheckMate-227 trial was presented by Suresh S. Ramalingam, M.D. and professor of hematology and medical oncology, in an oral poster session at this year’s ASCO20 Virutal Scientific program. The results of the CheckMate-227 study showed that novolumab in compilation with ipilimumab for NSCLC continued to show durable and long-term efficacy benefits, including a significant overall ...